Open access

Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer
Meng Qiao, Fei Zhou, Xinyu Liu, Tao Jiang, Haowei Wang, Yijun Jia, Xuefei Li, Chao Zhao, Lei Cheng, Xiaoxia Chen, Shengxiang Ren, Hongcheng Liu, Caicun Zhou

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005436; DOI: 10.1136/jitc-2022-005436
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
Paolo A Ascierto, Dirk Schadendorf

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005082; DOI: 10.1136/jitc-2022-005082
Correspondence on 'Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016' by Sussman et al
Christopher Grant, Garo Hagopian, Thuy B Tran, Gayathri Nagaraj, Justin T Moyers

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e006187; DOI: 10.1136/jitc-2022-006187
Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment
Hyunsu Kim, Sehhoon Park, Kyoung-Yeon Han, Naeun Lee, Hyemin Kim, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Se-Hoon Lee, Woong-Yang Park

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e005509; DOI: 10.1136/jitc-2022-005509
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
Iva Truxova, David Cibula, Radek Spisek, Jitka Fucikova

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e005968; DOI: 10.1136/jitc-2022-005968
TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells
Jiacheng Bi, Chen Huang, Xiaomeng Jin, Chaoyue Zheng, Yingying Huang, Xiaohu Zheng, Zhigang Tian, Haoyu Sun

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e006002; DOI: 10.1136/jitc-2022-006002
ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs in ovarian cancer
Huanhuan Chen, Keqing Yang, Lingxiao Pang, Jing Fei, Yongliang Zhu, Jianwei Zhou

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e005527; DOI: 10.1136/jitc-2022-005527
Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
WeiQing Venus So, David Dejardin, Eva Rossmann, Jehad Charo

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e006464; DOI: 10.1136/jitc-2022-006464
Liquid biopsies, are we ready for prime time?
Nicola Normanno, Kathi Apostolidis, Mark Stewart

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e006302; DOI: 10.1136/jitc-2022-006302
MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells
Yoshihiro Morimoto, Nami Yamashita, Tatsuaki Daimon, Haruka Hirose, Shizuka Yamano, Naoki Haratake, Satoshi Ishikawa, Atrayee Bhattacharya, Atsushi Fushimi, Rehan Ahmad, Hidekazu Takahashi, Olga Dashevsky, Constantine Mitsiades, Donald Kufe

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e006238; DOI: 10.1136/jitc-2022-006238

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages